Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: Prospective study of 91 cases who used a biological agent for more than 1 year

Modern Rheumatology

Volumn 19, Issue 4, 2009, Pages 390-394

  Sano, Hiroshige ^a   Arai, Katsumitsu ^a   Murai, Takehiro ^a   Fujisawa, Junichi ^a   Kondo, Naoki ^a   Netsu, Takahiro ^a   Hanyu, Tadamasa ^b   Saeki, Takako ^b   Ito, Tomoyuki ^b   Endo, Naoto ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NAGAOKA RED CROSS HOSPITAL   (Japan)

Author keywords

Anti TNF biological agent; Arthroplasty; Disease activity; Joint destruction; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTHROPLASTY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE INCLUDING 28 JOINT COUNT C REACTIVE PROTEIN; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; JOINT DESTRUCTION; JOINT SURGERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROPLASTY; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 68549092564     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0177-x     Document Type: Article

References (24)

1. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861-74.
2. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomized controlled trial. Lancet. 2004;363:675-81.
3. Landewe R, Van der Heijde D, Klareskog L, Van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate. Arthritis Rheum. 2006;54:3119-25.
4. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group; sustained improvement over two years in physical function. Structual damage and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051-65.
5. Smolen JS, van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis Rheum. 2006;54:702-10.
6. van Riel PL. Provisional guidelines for measuring disease activity in RA clinical trials. Br J Rheumatol. 1992;31:793-4.
7. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356-61.
8. Weaver AL. Efficacy and safety of the anti-TNF biological agents. Mod Rheumatol. 2004;14:101-12.
9. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis, 2002 update. Arthritis Rheum. 2002;46:328-46.
10. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45.
11. Breedvelt FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
12. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-602.
13. Keystone EC, Kavanaugh AF, Sharp JT, Tnannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-11.
14. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombination tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-9.
15. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261-3.
16. Larsen A, Dale K, EEK M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn. 1977;18:481-91.
17. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
18. van der Heijde DM, van Riel PL, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol. 1992;31:519-22.
19. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. comparison of disease activity score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407-9.
20. Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28-32.
21. Sano H, Arai K, Murai T, Fujisawa J, Endo N. Short-term results of etanercept in rheumatoid arthritis. Arch Niigata Soc Orthop Surg. 2007;23:51-4 (in Japanese).
22. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement. Arthritis Rheum. 2005;52:1020-30.
23. Abe A, Ishikawa H, Murasawa A, Nakazono K. Disease activity and the course of elbow joint deterioration over 10 years in the patients with early rheumatoid arthritis. Clin Rheumatol. 2007;27:867-72.
24. Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, et al. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis. 2008;67:1153-8.